Great to see another study w high efficacy of low-dose nivolumab (40mg Q2W; plus lenalidomide) in relapsed Hodgkin lymphoma: 90% ORR (60% CR, 30% PR), promising PFS & saturated PD1 receptor occupancy. Do we really need 240mg Q2W? www.sciencedirect.com/science/arti... @bloodjournals.hematology.org

Systematic review of low-dose anti-PD1 in Hodgkin lymphoma indicates comparable ORR, CR rates & toxicity to full dose aPD1 ascopubs.org/doi/10.1200/... Important open access publication @ascocancer.bsky.social JCO Global Oncology: Decrease costs and increase global health equity through aPD1 access?

Happy to share our latest publication For many in LMICs low-dose PD-1 blockers is the only way to afford this drugs and emergenig evidence suggests interesting things. Are we ready for more rigorous study of this intervention? ascopubs.org/doi/10.1200/...

Results from the AQUILA trial #ASH24 A few thoughts: - In absence of figures in uploaded abstracts, the n at risk table in the presentation is going to be important to pay attention to - How many of such progression events were SLiM? ash.confex.com/ash/2024/web...

Hung out with fellow @ash-hematology.bsky.social HONORS Alumnus @vaquerah-md.bsky.social & meet his classmate Rubi at ASH-a-Palooza! Learned so much about medical training in Mexico from these two. Watch out for these two amazing trainees who are changing the world! #ASHTrainee #ASHKudos #ASH24

We are loving the bracelets at #ASH24!

Ready to go! #ASH24

Badge ready, bags ready! See you tomorrow in #ASH24, looking forward to connect with other trainees tomorrow at ASH-a-Pallooza 🤩🩸

Finally time for #ASH24! Very excited to learn tons and connect with colleagues! Let's see whats new in #Lymphoma and #Myeloma 🙂‍↕️ Anyone open to chat about those topics and methods/stats, I would love it!

Our study found that nearly 40% (!) of 12-21 yo females are iron deficient. tinyurl.com/FeJAMA But did you know that in addition to many physical symptoms, iron deficiency is associated with multiple mental health issues? A #medsky #bluetorial 🧵1/

🎉📢 Delighted to share our work from Princess Margaret Cancer Centre 🙌🏼 PTCy-based GvHD prophylaxis was associated with an improved GRFS, NRM, and OS 💪🏼 A big shout-out to @haemophage.bsky.social for his mentorship 🙌🏼 doi.org/10.1182/bloo... #MedSky #HemeSky

Check out our new work in Annals of Hematology: ✅ 73% ORR ✅ 43% CR ⚠️ 61% Grade 1-2 AE ✅ No Grade 3-4 AE link.springer.com/article/10.1...